GAVI’S SUPPORT FOR IPV POST 2020

BOARD MEETING
Aurélia Nguyen
28-29 November 2018, Geneva
Polio eradication and Gavi’s engagement

**Gavi Alliance Board decisions**
- Time-limited support for mOPV stockpile
- Support IPV introduction with policy waivers
- IPV support through 2020 under existing arrangements
- Exceptional use of core resources to support IPV through 2020

**Polio Eradication events, milestones**
- 2005: GPEI funding
- 2017: GPEI funding
- 2018: POB request to fund IPV with core Gavi resources
- 2019: Decision on IPV investment case for post-2020 support

**Gavi 5.0**
- Board Meeting
  - 28-29 November 2018
Considerations of investment case

**Principles on IPV engagement**
- Polio eradication deemed a global public good, IPV is its “insurance policy”
- Gavi support will aim to align with SAGE recommendations
- Balance risk of IPV programme discontinuation against the principles of country ownership

**IPV & Hexavalent situation**
- All Gavi-supported countries expected to introduce IPV by Q2 2019
- Higher IPV prices during 2019-2022
- wP Hexavalent will be available in coming years
Investment options for standalone IPV

<table>
<thead>
<tr>
<th>Risk-based option</th>
<th>Gavi: $796 m</th>
<th>Countries: ---</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full support option</td>
<td>Gavi: $848 m</td>
<td>Countries: ---</td>
</tr>
</tbody>
</table>

Standard policies option
Gavi: $526 m
Countries: $249 m

Risk of IPV programme discontinuation
LOW
Gavi’s level of funding
HIGH

Board Meeting
28-29 November 2018
In principle support for Hexavalent vaccine

**Programmatic advantages**

- Potentially higher IPV coverage
- Fewer injections
- Lower cold chain requirements
- Minimalized risk of premature IPV discontinuation

**Risks**

- Reduced flexibility to remove IPV
- 4\textsuperscript{th} dose likely required
- Impact on IPV and Pentavalent markets to be closely managed

**Procurement cost to Gavi on Hexavalent support 2021-25**

- Full-support option: US$ 858 m
- Risk-based option: US$ 828 m
Recommendation (1/2)

The Gavi Alliance Programme and Policy Committee recommends to the Gavi Alliance Board that it:

a) **Approve**, subject to the availability of funding for the 2021-2025 period following Gavi’s replenishment for that period, support for inactivated poliovirus vaccine (IPV) under the arrangements agreed by the Board in November 2013 (Option 1 in paragraph 4.1 to Doc 12);

a) **Approve**, in-principle support for IPV containing whole-cell pertussis Hexavalent vaccine (Hexavalent) for the administration of IPV, diphtheria, tetanus, whole-cell pertussis, hepatitis B and Haemophilus influenza b antigens, subject to a vaccine being licenced, recommended for use by WHO, WHO pre-qualified and that market attributes support the successful implementation of Hexavalent;
c) **Note** that the financial implications associated with these decisions are expected to be approximately US$ 850 million (of which an estimated US$ 848 million is dedicated to standalone IPV) for the period 2021-2025 and that, given that financing for IPV was not included in the investment case for the replenishment in 2015, funds for IPV support beyond 2020 should be considered as additional to other Gavi investments.
Thank you